Interstitial cystitis is a condition with no cure, no universally effective treatment, and a patient population that is over 80% female. When a 2024 pilot study reported that BPC-157 injections resolved symptoms in 10 of 12 women with severe IC who had failed standard treatment, the chronic pain community paid attention. Here’s what the study showed, what the limitations are, and why this matters.
In 2024, a pilot study was published examining BPC-157 as a treatment for interstitial cystitis. Twelve women between the ages of 39 and 76 (mean age 58.3) with moderate to severe IC participated. All 12 had previously failed pentosan polysulfate (the standard oral treatment). None had responded to conventional therapy.
The women underwent cystoscopy and received intravesical injections of BPC-157 (total of 10 mg) around the areas of bladder wall inflammation during a single procedure.
The results: Complete resolution of symptoms was reported in 10 of 12 patients (83%), who rated their improvement at 100% on the Global Response Assessment. The remaining 2 patients rated their improvement at 80%, with most symptoms resolved but about 20% lingering. All 12 patients scored 5/5 on the Global Response Assessment. No adverse events were reported. No patient dropped out.
Before getting too excited, it’s essential to understand this study’s significant limitations:
A review paper summarizing this study called the results “encouraging” but noted that a separate small study involving intra-articular BPC-157 injections demonstrated improved pain in 87.5% of patients but suffered from similar design limitations: small sample size, no control group, no standardized diagnosis criteria.
Even with the study’s limitations, the mechanistic rationale for BPC-157 in IC is plausible. IC is characterized by bladder wall inflammation, damage to the glycosaminoglycan (GAG) layer that protects the bladder lining, and dysfunction of tissue repair mechanisms. BPC-157 has demonstrated anti-inflammatory activity, promotion of angiogenesis and tissue healing, enhanced collagen production, and cytoprotective effects on mucosal surfaces in extensive preclinical research.
These properties align with the pathophysiology of IC. The question isn’t whether BPC-157 could help IC — it’s whether it does in controlled, blinded, adequately powered human trials. Those trials don’t exist yet.
If you have IC, this study is a reason for cautious optimism, not a reason to seek out BPC-157 injections immediately. The ideal next steps would be independent replication of these results by researchers without financial conflicts, a randomized controlled trial with a placebo arm, objective outcome measures alongside patient-reported symptoms, and longer-term follow-up to determine durability of response.
An important regulatory note: as of April 2026, BPC-157 is not eligible for 503A compounding in the United States. No licensed U.S. compounding pathway currently exists for this peptide. Access is limited to research peptide vendors (not intended for human use) or, potentially, through a 503B outsourcing facility.
Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. It disproportionately affects women — over 80% of IC patients are female. Approximately 7.9 million adult women in the U.S. are affected. It costs the healthcare system over $100 million annually in direct costs and lost productivity.
The pilot study used intravesical BPC-157 injections — meaning the peptide was injected directly into the bladder wall during a cystoscopy procedure performed by a urologist. This is not something that can be done at home. Subcutaneous BPC-157 injections (the standard self-administration method) have not been studied for IC. The delivery method matters.
The pilot study has significant limitations: small sample size (12 women), no control group, no blinding, no objective outcome measures, and the authors were affiliated with the clinic selling BPC-157 injections. A review paper noted the results were encouraging but called for independent, controlled research. This is preliminary evidence that needs replication.
Pentosan polysulfate (Elmiron) was the standard oral treatment but has been linked to pigmentary maculopathy with long-term use. Bladder instillations (DMSO, heparin, lidocaine combinations), pelvic floor physical therapy, dietary modifications, and neuromodulation are other options. No treatment is universally effective, which is why new approaches like BPC-157 generate significant interest.